GUFIC BIOSCIENCE share price has zoomed 7% and is presently trading at Rs 428.1.
Meanwhile, the BSE HEALTHCARE index is at 44,161.6 (up 0.7%).
Among the top gainers in the BSE HEALTHCARE index today are HIKAL CHEMIC (up 5.8%) and Natco Pharma (up 3.9%).
ERIS LIFESCIENCES (down 1.3%) and SYNGENE INTERNATIONAL (down 1.2%) are among the top losers today.
Over the last one year, GUFIC BIOSCIENCE has moved up from Rs 296.5 to Rs 428.1, registering a gain of Rs 131.6 (up 44.4%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,436.8 to 44,161.6, registering a gain of 55.3% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were SUVEN PHARMACEUTICALS (up 131.0%), Jubilant Pharmova (up 129.2%) and GRANULES INDIA (up 120.2%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,996.4 (up 0.1%).
The top gainers among the BSE Sensex today are Asian Paints (up 2.3%) and Bajaj Finance (up 1.9%). The most traded stocks in the BSE Sensex are Tata Motors and MUNDRA PORT & SEZ.
In the meantime, NSE Nifty is at 25,070.0 (up 0.1%). Bajaj Auto and Asian Paints are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 67,127.1 to 81,996.4, registering a gain of 14,869.3 points (up 22.2%).
GUFIC BIOSCIENCE net profit grew 1.1% YoY to Rs 209 million for the quarter ended June 2024, compared to a profit of Rs 206 million a year ago. Net sales rose 4.0% to Rs 2,028 million during the period as against Rs 1,950 million in April-June 2023.
For the year ended March 2023, GUFIC BIOSCIENCE reported 16.8% decrease in net profit to Rs 797 million compared to net profit of Rs 958 million during FY22. Revenue of the company fell 11.4% to Rs 6,906 million during FY23.
The current Price to earnings ratio of GUFIC BIOSCIENCE, based on rolling 12 month earnings, stands at 49.7.
Equitymaster requests your view! Post a comment on "GUFIC BIOSCIENCE Gains 7%; BSE HEALTHCARE Index Up 0.7%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!